Ontario Providing Access to Lifechanging Treatment for Cystic Fibrosis PatientsPublished on September 24, 2021
The government is taking urgent action to ensure all cystic fibrosis patients will have more timely access to the effective and lifechanging treatments they need.
In addition to the drugs Orkambi and Kalydeco, the first drugs in this class to treat cystic fibrosis and currently funded through the Ontario Drug Benefit program, Ontario is now providing coverage for Trikafta, the latest and most effective treatment option for cystic fibrosis to become available, under its publicly-funded drug program to give patients more access to lifechanging treatments for cystic fibrosis.
Ontario patients aged 12 and up who do not meet the lung function criteria may work with their clinician to apply to the Exceptional Access Program to be considered for funding on a case-by-case basis.
Providing coverage for Trikafta is one more way the government is building a sustainable, modern and connected health care system that will expand coverage to new and innovative treatments and provide high-quality health care to patients for years to come.